Fwd: Pleural Mesothelioma Diagnosis - Family Reaction

---------- Forwarded message ----------
From: blinkx SmartFeed: mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Tue, May 6, 2008 at 8:34 PM
Subject: Pleural Mesothelioma Diagnosis - Family Reaction
To: collegeschoolloan@gmail.com


In 2001 Joe Trocki was diagnosed with pleural mesothelioma. In this video his daughter Patti shares how the family reacted. For more information visit:...

smartfeed@blinkx.com Mon, 05 May 2008 19:45:20 GMT

___
Source: http://www.blinkx.com/video/YouTube/Pleural_Mesothelioma_Diagnosis_-_Family_Reaction~vqSHeZvpkrrgnNk54JhmXMw&referrer=website_rss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Wed, Jun 18, 2008 at 9:55 AM
Subject: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)
To: collegeschoolloan@gmail.com


Clinica - the world's leading news service for the medical technology industry - has learned that staff and visitors to London's Houses of Parliament have been at risk of exposure to high levels of asbestos contamination for significant periods during the last three years.

Tue, 17 Jun 2008 09:26:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=12146ord8/*http%3A//biz.yahoo.com/prnews/080617/3682401en_public.html?.v=1
--
 

Fwd: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
To: mesothelioma77@gmail.com


[1]Radiology. 2008 Jul; 248(1): 79-87
Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM

PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board and was HIPAA compliant; informed consent was waived. From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers. Forty-eight women (mean age, 49.1 years; range, 29.7-72.4 years) were divided into recurrence-free or recurrence groups. Volume measurements were tabulated for SER values between set ranges; cutoff criteria were defined to predict disease recurrence after surgery. Wilcoxon rank sum tests and the multivariate Cox proportional hazards regression model were used for evaluation. RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence. Seventy-five percent of patients with recurrence and 100% of deceased patients were identified as being at high risk for recurrence. Thirty percent of patients with recurrence and 67% of deceased patients were identified as having high risk before chemotherapy. No patients in the recurrence-free group were misidentified as likely to have recurrence. All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups. The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence. Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038). CONCLUSION: High-spatial-resolution SER imaging may improve prediction for patients at high risk for disease recurrence and death.



___
Source: http://www.hubmed.org/display.cgi?uids=18566170
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Lung tumours, primary and secondary]

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [Lung tumours, primary and secondary]
To: mesothelioma77@gmail.com


[1]Rev Prat. 2008 Feb 29; 58(4): 435-43
Urban T, Hureaux J, Leguen Y





___
Source: http://www.hubmed.org/display.cgi?uids=18506986
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F

We have previously shown that ovarian tumors express prostate-derived Ets transcription factor (PDEF). However, the precise role of PDEF in the prognosis of ovarian cancer is unknown. In our study, we report for the first time that expression of PDEF in tumor lesions of patients with ovarian cancer is associated with favorable prognosis. Evaluation of samples from 40 patients with ovarian cancer showed that early stage (IA) and borderline (IIB, III) ovarian tumors expressed higher levels of PDEF mRNA and protein and lower levels of survivin compared to late stage ovarian tumors (IIIC and IV, p

___
Source: http://www.hubmed.org/display.cgi?uids=18567002
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Family history of cancer and stomach cancer risk.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Family history of cancer and stomach cancer risk.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Foschi R, Lucenteforte E, Bosetti C, Bertuccio P, Tavani A, La Vecchia C, Negri E

A family history of stomach cancer in first-degree relatives increases the risk of stomach cancer, but uncertainties remain as concerns the variation of the risk according to age, sex and type of relative, as well as on the role of family history of other cancers. We investigated the issue using data from a multicentric case-control study conducted in Italy between 1997 and 2007 on 230 cases aged not more than 80 years, with histologically confirmed incident gastric cancer and 547 controls admitted to hospital for acute, non neoplastic conditions. Logistic regression models adjusted for the effect of sex, age, year of interview, education, body mass index (BMI), tobacco smoking and number of brothers and sisters were used to estimate the odds ratios (OR) of stomach cancer. Relative to subjects with no history, those with a family history of gastric cancer had an OR of 2.5 (95% confidence interval (CI) 1.5-4.2). No significant heterogeneity emerged according to sex or age of the proband or of the affected relative, or smoking habits, BMI and education of the proband. As suggested from previous studies the OR was higher when the affected relative was a sibling (OR=5.1, 95% CI: 1.3-20.6) rather than a parent (OR=2.2, 95% CI: 1.2-3.9), although the heterogeneity test was not significant. The risk of stomach cancer was not increased in subjects with a family history of cancer at any other site. The OR for all sites excluding stomach was 1.0 (95% CI: 0.7-1.4). (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18567000
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc